Director of Helix BioPharma Corp. Acquires a Further 1,000,000 Common Shares
10 Gennaio 2014 - 4:36PM
Marketwired
Director of Helix BioPharma Corp. Acquires a Further 1,000,000
Common Shares
AURORA, ON--(Marketwired - Jan 10, 2014) - Helix BioPharma Corp.
(TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company dedicated
to developing drugs for prevention and treatment of cancer, today
announced that it has been advised by Dr. Marek Orlowski, a member
of the board of directors of Helix and Chairman of the Supervisory
Board of Helix Polska, that he has purchased 1,000,000 previously
issued and outstanding shares of Helix for a total purchase price
of approximately CAD$1.72 million since December 30, 2013.
Dr. Orlowski now holds an aggregate of 1,710,000 shares of
Helix.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix's
product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently
listed on the TSX and FSE under the symbol "HBP".
Investor Relations: Helix BioPharma Corp. Tel : 905 841-2300
Email: ir@helixbiopharma.com
Grafico Azioni Helix BioPharma (TSX:HBP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Helix BioPharma (TSX:HBP)
Storico
Da Giu 2023 a Giu 2024